If the pharmaceutical manufacturer has a lot of suppliers, then these suppliers also needs to be assessed by classifying them into diverse levels dependent on their impact on the medicinal products.“It can make it difficult to propose that bringing all of the API manufacturing back again to your US and Europe solves the issue. It doesn’t if we